Cannabis Law Report recently highlighted Students for Sensible Drug Policy’s work advocating for a science-based, harm reduction approach to kratom, 7-hydroxymitragynine (7-OH), and emerging products.

The article spotlights SSDP’s recent webinar, “Kratom, 7-OH, and Emerging Products: A Science-Based Safety Primer,” which brought together experts and advocates to examine what the research actually tells us about these substances — including potential risks, harm reduction strategies, and regulatory approaches that can protect consumers without resorting to prohibition.

The coverage also highlights SSDP’s opposition to efforts to place 7-OH into Schedule I. As we have argued throughout this fight, legitimate concerns about product safety do not justify repeating the mistakes of the War on Drugs. Criminalization can create new barriers to scientific research, restrict exploration of potential therapeutic applications, and push consumers toward illicit and unregulated markets.

There is a better approach.

Rather than prohibition, SSDP supports evidence-based regulations including product testing, accurate labeling, age restrictions, and quality-control standards designed to give consumers better information and reduce harm.

As policymakers across the country grapple with kratom, 7-OH, and other emerging substances, SSDP will continue fighting for policies grounded in science, harm reduction, and human rights — not fear, stigma, or another chapter of the War on Drugs.

Read the full coverage from Cannabis Law Report:
SSDP Advocates for Science-Based Approaches to 7-OH and Kratom Policy